Literature DB >> 23059762

Perspectives on medicinal properties of plumbagin and its analogs.

Subhash Padhye1, Prasad Dandawate, Mujahid Yusufi, Aamir Ahmad, Fazlul H Sarkar.   

Abstract

Plumbagin is one of the simplest plant secondary metabolite of three major phylogenic families viz. Plumbaginaceae, Droseraceae, and Ebenceae, and exhibits highly potent biological activities, including antioxidant, antiinflammatory, anticancer, antibacterial, and antifungal activities. Recent investigations indicate that these activities arise mainly out of its ability to undergo redox cycling, generating reactive oxygen species and chelating trace metals in biological system. The compound is endowed with a property to inhibit the drug efflux mechanism in drug-resistant bacteria, thereby allowing intracellular accumulation of the potent drug molecules. An interesting bioactivity exhibited by this compound is the elimination of stringent, conjugative, multidrug-resistant plasmids from several bacterial strains including opportunistic bacteria, such as Acinetobacter baumannii. Moreover, plumbagin effectively induces apoptosis and causes cell cycle arrest, which is, in part, due to the inactivation of NF-κB in cancer cells. Therefore, it has been suggested that designing "hybrid drug molecules" of plumbagin by combining it with other appropriate anticancer agents may lead to the generation of novel and potent anticancer drugs with pleiotropic action against human cancers. This comprehensive review is an attempt to understand the chemistry of plumbagin and catalog its biological activities reported to date.
© 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 23059762     DOI: 10.1002/med.20235

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  76 in total

1.  Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone), isolated from Plumbago zeylanica, inhibits ultraviolet radiation-induced development of squamous cell carcinomas.

Authors:  Jordan M Sand; Bilal Bin Hafeez; Mohammad Sarwar Jamal; Olya Witkowsky; Emily M Siebers; Joseph Fischer; Ajit K Verma
Journal:  Carcinogenesis       Date:  2011-11-09       Impact factor: 4.944

Review 2.  Protein lysine acetylation by p300/CBP.

Authors:  Beverley M Dancy; Philip A Cole
Journal:  Chem Rev       Date:  2015-01-16       Impact factor: 60.622

3.  Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells.

Authors:  Jia-Xuan Qiu; Zhi-Wei Zhou; Zhi-Xu He; Ruan Jin Zhao; Xueji Zhang; Lun Yang; Shu-Feng Zhou; Zong-Fu Mao
Journal:  Drug Des Devel Ther       Date:  2015-01-07       Impact factor: 4.162

4.  Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo.

Authors:  Sutapa Sinha; Krishnendu Pal; Ahmed Elkhanany; Shamit Dutta; Ying Cao; Gourish Mondal; Seethalakshmi Iyer; Veena Somasundaram; Fergus J Couch; Viji Shridhar; Resham Bhattacharya; Debabrata Mukhopadhyay; Priya Srinivas
Journal:  Int J Cancer       Date:  2012-07-27       Impact factor: 7.396

5.  Inhibiting the Activity of NADPH Oxidase in Cancer.

Authors:  Mariam M Konaté; Smitha Antony; James H Doroshow
Journal:  Antioxid Redox Signal       Date:  2020-04-17       Impact factor: 8.401

6.  Plumbagin Inhibits Prostate Carcinogenesis in Intact and Castrated PTEN Knockout Mice via Targeting PKCε, Stat3, and Epithelial-to-Mesenchymal Transition Markers.

Authors:  Bilal Bin Hafeez; Joseph W Fischer; Ashok Singh; Weixiong Zhong; Ala Mustafa; Louise Meske; Mohammad Ozair Sheikhani; Ajit Kumar Verma
Journal:  Cancer Prev Res (Phila)       Date:  2015-01-27

Review 7.  The Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome.

Authors:  Yiwei Li; Vay Liang W Go; Fazlul H Sarkar
Journal:  Pancreas       Date:  2015-01       Impact factor: 3.327

Review 8.  Targeting SH2 domains in breast cancer.

Authors:  Pietro Morlacchi; Fredika M Robertson; Jim Klostergaard; John S McMurray
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

9.  Plumbagin exhibits an anti-proliferative effect in human osteosarcoma cells by downregulating FHL2 and interfering with Wnt/β-catenin signalling.

Authors:  Yuan-Liang Xue; Xiang-Qi Meng; Long-Jun Ma; Zhen Yuan
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

Review 10.  Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy.

Authors:  Prasad R Dandawate; Dharmalingam Subramaniam; Roy A Jensen; Shrikant Anant
Journal:  Semin Cancer Biol       Date:  2016-09-05       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.